Participated · Debt Financing · Feb 2025

STAX Engineering designs and operates a patented, flexible barge-based exhaust capture system that connects to ship stacks from the water to capture and filter emissions without vessel modification or berth-specific infrastructure. Its system is authorized by CARB for container ships, auto carriers, and tankers and is reported to remove up to 99% of particulate matter and 95% of nitrogen oxides. STAX began tanker service testing in early 2025, has supported tanker operations in Southern California since 2024, and has completed over 2,700 vessel calls totalling more than 46,000 treated hours and capturing over 350 tons of pollutants. Recent commercial agreements with IMTT and TransMontaigne expand its Northern California footprint and are expected to support more than 6,400 at-berth service hours through 2031. The company plans to scale deployments across California’s ports to meet demand ahead of CARB’s 2027 tanker compliance deadline. Its current financial position was strengthened by the $150 million financing commitment from Bain Capital to refinance existing debt and fund contracted builds through 2027.

Participated · Equity · Oct 2024

FeelBetter has developed an AI-based Pharmaco-Clinical Intelligence platform with four core tools: Insight (risk stratification), Navigator (workflow management), Action (AI decision-support for pharmacists) and Impact (post-intervention monitoring). The company reports reaching more than 300,000 patients daily and cites partnerships with Leumit HMO, Atlantic Health, and a retrospective study at Brigham & Women’s Hospital validating its outcomes. Published and partner-reported results include large reductions in hospital admissions and days, clinical improvements in LDL and HbA1c, a 5x increase in pharmacist capacity reported by Leumit, and estimated cost savings per high-risk patient. FeelBetter has raised $11.5 million from grants and investors to date and is actively seeking Series A funding. The firm says it is expanding its global footprint and plans to partner with more U.S.-based health systems to pursue broader adoption of its population- and individual-level solution.

Led · Series A · Aug 2024

Baibys has developed an autonomous sperm selection system for in‑vitro fertilization that analyzes living sperm cells in real time using machine vision and artificial intelligence. The platform evaluates cells by high‑magnification morphological criteria and recognizes structures in motion to assess quality. It then autonomously selects and collects sperm with the highest fertilization potential for microinjection into the egg during IVF procedures. The company says the system relies on state‑of‑the‑art AI algorithms to apply previously established selection criteria. Baibys plans to use newly raised capital to expand operations, advance development efforts, and broaden its business reach. The team includes chairman Itay Itzhaky, CEO Dr. Yaron Silberman, co‑founder & co‑CEO Gal Golov, co‑founder & CMO Dr. Nino Guy Cassuto, and senior R&D and regulatory leaders.

Participated · Seed · May 2024

Remepy develops Hybrid Drugs that integrate prescription medicines with personalized, AI-driven therapeutic apps to combine pharmacology with adaptive physical, cognitive, and behavioral interventions. The company partners with pharmaceutical firms to co-develop these drug–software combination products and recently announced a strategic collaboration with Merck KGaA. Remepy’s lead program, Hybridopa for Parkinson’s disease, produced encouraging Phase IIa results supported by peer‑reviewed publications and is being prepared for a global Phase III trial expected to begin in Q4 2026. The Series A financing and existing investor base have brought total capital raised to $62 million, providing funds to expand the company’s pipeline, platform, and pharmaceutical partnerships. Remepy positions its approach within emerging FDA frameworks for drug‑software combination products and aims to create new IP and lifecycle-management opportunities for partner drugs.

Led · Equity · Aug 2023

FeelBetter offers a SaaS-based Pharmaco-Clinical Intelligence platform that synthesizes and analyzes healthcare data from multiple sources to pinpoint patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management. The platform proactively suggests immediate, actionable interventions to reduce polypharmacy risks. It also aids healthcare providers in monitoring patients’ progress and measuring the impact of clinical interventions. By using FeelBetter, provider organizations can allocate resources to serve patients and minimize preventable, costly use of healthcare services. The company is led by CEO and co-founder Liat Primor and CTO/COO and co-founder Yoram Hordan, and is based in Boston, MA and Tel Aviv, Israel. Financially, the company raised $5.9M in the latest round, bringing total funding to $8M.